UNIVEST FINANCIAL Corp Has $9.62 Million Stake in Johnson & Johnson (NYSE:JNJ)

UNIVEST FINANCIAL Corp lessened its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,464 shares of the company’s stock after selling 403 shares during the quarter. Johnson & Johnson makes up approximately 3.0% of UNIVEST FINANCIAL Corp’s investment portfolio, making the stock its 6th largest position. UNIVEST FINANCIAL Corp’s holdings in Johnson & Johnson were worth $9,621,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in JNJ. Nordwand Advisors LLC bought a new position in Johnson & Johnson during the 4th quarter worth approximately $785,273,000. Savant Capital LLC raised its holdings in Johnson & Johnson by 8,568.8% during the 4th quarter. Savant Capital LLC now owns 3,630,127 shares of the company’s stock worth $29,637,000 after purchasing an additional 3,588,251 shares during the last quarter. Edmp Inc. raised its holdings in Johnson & Johnson by 17,222.9% during the 4th quarter. Edmp Inc. now owns 3,223,265 shares of the company’s stock worth $18,247,000 after purchasing an additional 3,204,658 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Johnson & Johnson by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after acquiring an additional 2,815,655 shares in the last quarter. Finally, GQG Partners LLC increased its stake in shares of Johnson & Johnson by 64.4% in the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock valued at $1,151,931,000 after acquiring an additional 2,547,378 shares in the last quarter. Institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $158.91 on Monday. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $183.35. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. The company has a market capitalization of $412.96 billion, a P/E ratio of 33.24, a price-to-earnings-growth ratio of 2.71 and a beta of 0.53. The company’s 50-day moving average is $159.70 and its 200 day moving average is $166.20.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.51 by $0.17. The business had revenue of $24.75 billion during the quarter, compared to analyst estimates of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. Johnson & Johnson’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.67 earnings per share. On average, equities research analysts forecast that Johnson & Johnson will post 10.66 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be paid a $1.19 dividend. The ex-dividend date is Monday, May 22nd. This represents a $4.76 annualized dividend and a yield of 3.00%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio is currently 94.56%.

Insider Activity

In other news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on JNJ shares. Guggenheim started coverage on shares of Johnson & Johnson in a research note on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Piper Sandler lowered their price objective on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Atlantic Securities lowered their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research note on Wednesday, April 19th. Finally, StockNews.com began coverage on shares of Johnson & Johnson in a research report on Thursday. They issued a “strong-buy” rating for the company. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $173.00.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.